Global Health Concerns: Rising TB, Bird Flu in Mammals, and Pharmaceutical Updates

Recent health news highlights a 10% rise in child TB infections in Europe, detected mammal bird flu cases, and economic impacts on drug companies. WHO urges action on TB, GSK seeks approval for Nucala, fears over UK's bird flu case increase, and two major pharmaceutical acquisitions unfold.

A recent surge in child tuberculosis infections in the European region has triggered an urgent call for action from the World Health Organization. With a 10% rise in 2023, health experts are alarmed at the continued transmission.

Simultaneously, the spread of bird flu to mammals, including a sheep in England, is escalating global pandemic fears, as regulators in Europe contemplate approving GSK's asthma drug Nucala for additional COPD treatments.

Meanwhile, pharmaceutical giants like Novo Nordisk make strategic moves amid fluctuating market concerns, such as Novo's progressive expansion in the obesity sector through a billion-dollar acquisition, revealing the complex interplay between health crises and industry dynamics.

(With inputs from agencies.)